Breaking News Instant updates and real-time market news.

INSY

Insys Therapeutics

$7.96

0.31 (4.05%)

, DEPO

Depomed

$6.67

0.21 (3.25%)

07:21
02/13/18
02/13
07:21
02/13/18
07:21

Senate report says opioid makers paid millions to advocacy groups, Reuters says

Opioid manufacturers Purdue Pharma, Insys Therapeutics (INSY), Depomed (DEPO), Johnson & Johnson (JNJ) and Mylan (MYL) have paid over $10M to advocacy groups and doctors linked to them, many of whom amplified industry support of the use of painkillers, Reuters says, citing a U.S. Senate report by Democratic Senator Claire McCaskill. Insys Therapeutics, which makes pain drug Subsys and gave $3.15M to U.S. Pain Foundation and others, has seen several former Insys executives and employees, including billionaire founder John Kapoor, accused by federal prosecutors of engaging in a scheme to pay kickbacks to doctors to prescribe Subsys. Reference Link

INSY

Insys Therapeutics

$7.96

0.31 (4.05%)

DEPO

Depomed

$6.67

0.21 (3.25%)

JNJ

Johnson & Johnson

$130.27

0.74 (0.57%)

MYL

Mylan

$40.60

1.32 (3.36%)

  • 13

    Feb

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 21

    Feb

  • 08

    Mar

  • 13

    Nov

INSY Insys Therapeutics
$7.96

0.31 (4.05%)

07/21/17
JANY
07/21/17
NO CHANGE
Target $16
JANY
Buy
Subsys ANDA somewhat negative for Insys, but not unexpected, says Janney Capital
Janney Capital analyst Ken Trbovich noted that the FDA's Paragraph IV certifications list earlier this week showed that Insys had received an ANDA filing for Subsys on May 22, which he views as "somewhat negative," but also "not unexpected." While the ANDA raises the possibility of a generic sooner rather than later, Trbovich sees no risk for a generic Subsys until 2020 at the earliest and thinks the company's patents could prevent generic entry until as late as 2030. He keeps a Buy rating and $16 fair value estimate on Insys shares.
05/10/17
PIPR
05/10/17
DOWNGRADE
Target $10
PIPR
Neutral
Insys Therapeutics downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst David Amsellem downgraded Insys Therapeutics to Neutral following the Q1 results and halved his price target for the shares to $10 from $20. Prescription trends for Subsys have been consistently weak and will remain so given the scrutiny of the opioid space and Insys in particular, Amsellem tells investors in a post-earnings research note.
04/06/17
OPCO
04/06/17
NO CHANGE
OPCO
Perform
DoJ settlement not 'end all, be all' for Insys Therapeutics, says Oppenheimer
Oppenheimer analyst Derek Archila thinks Insys Therapeutics' shares are likely to react favorably on an announcement of a DoJ settlement, but he does not view it as the "end all, be all" clearing event for the company as he continues to worry about deteriorating Subsys sales and consensus forecasts for Syndros that look too high. The analyst reiterates a Perform rating on the shares.
03/24/17
JANY
03/24/17
NO CHANGE
Target $19
JANY
Buy
Janney says Insys receipt of DEA decision removes 'stonewalling' fear
Janney Capital analyst Ken Trbovich said Insys Therapeutics' receipt of DEA scheduling of Syndros sets up a launch in the second half of the year, giving its sales reps a second product to promote and the company an opportunity to return to growth. Furthermore, the decision removes uncertainty about whether the company's ongoing DOJ investigation led to "stonewalling" of the company's regulatory efforts, noting that "while slow," both the DEA and FDA eventually took action. He keeps a Buy rating and $19 fair value estimate on Insys shares.
DEPO Depomed
$6.67

0.21 (3.25%)

12/05/17
12/05/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McDonald's (MCD) upgraded to Buy from Hold at Jefferies with analyst Andy Barish saying McDonald's is well positioned in the current environment to continue to outperform. 2. Snap (SNAP) upgraded to Overweight from Equal Weight at Barclays with analyst Ross Sandler sayign with the company's pricing transition in the later stages, Snap may start hitting or exceeding consensus revenue estimates and accelerating growth in 2018. 3. Depomed (DEPO) upgraded to Buy from Neutral at Mizuhom with analyst Irina Koffler citing the company's agreement to license rights to commercialize the Nucynta franchise to Collegium (COLL). 4. United Technologies (UTX) upgraded to Overweight from Neutral at Atlantic Equities. 5. Earthstone Energy (ESTE) upgraded to Buy from Neutral at Seaport Global with analyst Mike Kelly citing the October 18 capital raise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/05/17
12/05/17
UPGRADE
Target $9

Buy
Depomed upgraded to Buy after opiod exit deal at Mizuho
As previously reported, Mizuho analyst Irina Koffler upgraded Depomed (DEPO) to Buy from Neutral after the company agreed to license rights to commercialize the Nucynta franchise to Collegium (COLL). With the deal, Depomed exits the opioid space and significantly lowers its operating expenses, said Koffler, who raised her price target on Depomed shares to $9 from $6.
12/05/17
NEED
12/05/17
NO CHANGE
Target $28
NEED
Buy
Collegium Pharmaceutical price target raised to $28 from $25 at Needham
Needham analyst Serge Belanger raised his price target on Collegium Pharmaceutical (COLL) after its agreement with Depomed (DEPO) to license U.S. commercial rights of Nucynta and Nucynta ER. Belanger says the transaction allows the company to "leverage its commercial infrastructure given the significant overlap with Xtampza's target audience of pain specialists", estimating that it adds about $3-$5 to the company valuation. The analyst keeps his Buy rating on Collegium Pharmaceutical, noting that the deal moves up the timelines for profitability.
12/05/17
MZHO
12/05/17
UPGRADE
MZHO
Buy
Depomed upgraded to Buy from Neutral at Mizuho
JNJ Johnson & Johnson
$130.27

0.74 (0.57%)

02/06/18
WELS
02/06/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson talc litigation concerns appear overblown, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen says Johnson & Johnson shares were down partly due to concerns about ongoing litigation over allegations that its talcum power products are unsafe for use because they contain asbestos which can cause mesothelioma. Based on prior high-profile product liability cases in the drug and device sectors, the analyst believes any potential settlement would be manageable for Johnson & Johnson. He reiterates an Outperform rating and $160 price target on the shares.
01/18/18
MSCO
01/18/18
NO CHANGE
Target $157
MSCO
Equal Weight
Zytiga ruling a headwind, but doesn't change J&J thesis, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Johnson & Johnson suffered an adverse Zytiga IPR ruling, which he calls an incremental headwind. However, he added that a possible earlier generic Zytiga entry is irrelevant to his net present value for J&J shares and doesn't change his view that its Pharma growth accelerates in 2018. Lewis keeps an Equal Weight rating and $157 price target on J&J shares.
01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MYL Mylan
$40.60

1.32 (3.36%)

01/24/18
DBAB
01/24/18
NO CHANGE
Target $50
DBAB
Buy
Mylan target raised to $50 on biosimilar opportunity at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert raise his price target for Mylan to $50 from $48 saying biosimilars could be an important driver of longer-term growth. Mylan has one of the largest biosimilar pipelines in the industry and could launch its first biosimilar in the U.S., pegfilgrastim, this year, Gilbert tells investors in a research note. He keeps a Buy rating on the shares.
01/18/18
LEER
01/18/18
NO CHANGE
LEER
Hospitals' entrant could add to generic industry headwinds, says Leerink
After the New York Times reported that a number of the U.S.'s largest hospital systems plan to create a non-profit generic drug company to fight high prices and drug shortages, Leerink analyst Ami Fadia said she doesn't expect this to have an immediate significant impact on pricing, but does view the news as a continuation of the pricing headwinds seen over the past few years. While unclear what development stage the new generics company is at, the formation of such a company would add one more occupant in an already crowded space, added Fadia. Companies in the generic drug space include Teva (TEVA), Mylan (MYL), Novartis (NVS), Endo (ENDP) and Impax (IPXL).
01/18/18
CANT
01/18/18
NO CHANGE
CANT
Report of hospital plans for generic drug company 'just noise,' says Cantor
Cantor Fitzgerald analyst Louise Chen said that concerns about hospitals possibly manufacturing their own generic drugs, spurred by a New York Times article discussing the subject, are overdone. Generics companies who responded to the analyst noted that sterile manufacturing is very difficult and drug approvals and plant inspections take time, so any opportunity for hospitals is likely many years away at best, unless they decided to acquire a company, said Chen. The analyst, who said the headlines are "just noise," has Neutral ratings on Endo (ENDP), Mylan (MYL) and Teva (TEVA) and an Overweight rating on Impax (IPXL).
01/18/18
WELS
01/18/18
NO CHANGE
Target $43
WELS
Market Perform
Mylan price target raised to $43 from $33 at Wells Fargo
Wells Fargo analyst David Maris raised his price target for Mylan to $43 from $33 as he believes it will likely have an eventful year. The analyst reiterates a Market Perform rating on the shares.

TODAY'S FREE FLY STORIES

AMSWA

American Software

$14.94

-0.21 (-1.39%)

04:52
06/22/18
06/22
04:52
06/22/18
04:52
Recommendations
American Software analyst commentary  »

American Software price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

02:10
06/22/18
06/22
02:10
06/22/18
02:10
General news
OPEC and allies, reached preliminary deal on output »

OPEC and allies, reached…

02:00
06/22/18
06/22
02:00
06/22/18
02:00
General news
Asian Market Wrap: »

Asian Market Wrap:…

TSLA

Tesla

$347.49

-14.69 (-4.06%)

21:14
06/21/18
06/21
21:14
06/21/18
21:14
Periodicals
Tesla job cuts to concentrate on the solar facilities, Reuters says »

As part of the 9% staff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

ECOR

ElectroCore

$0.00

(0.00%)

21:08
06/21/18
06/21
21:08
06/21/18
21:08
Syndicate
ElectroCore 5.2M share IPO priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

TELNY

Telenor

$0.00

(0.00%)

20:43
06/21/18
06/21
20:43
06/21/18
20:43
Upgrade
Telenor rating change at JPMorgan »

Telenor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMX

CarMax

$71.05

-1.77 (-2.43%)

20:25
06/21/18
06/21
20:25
06/21/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$274.28

-1.72 (-0.62%)

, SPX

S&P 500

$0.00

(0.00%)

20:07
06/21/18
06/21
20:07
06/21/18
20:07
Periodicals
Money market funds pull the most funds since 2011, Reuters says »

Investors pulled $51B in…

SPY

SPDR S&P 500 ETF Trust

$274.28

-1.72 (-0.62%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANZBY

ANZ Banking

$0.00

(0.00%)

19:53
06/21/18
06/21
19:53
06/21/18
19:53
Hot Stocks
ANZ Bank doubles share buyback to AUD 3B »

ANZ announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$185.48

-1.06 (-0.57%)

, QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

19:50
06/21/18
06/21
19:50
06/21/18
19:50
Periodicals
Apple challenges four patents held by Qualcomm at USPTO, Bloomberg says »

Apple (AAPL) filed…

AAPL

Apple

$185.48

-1.06 (-0.57%)

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CS

Credit Suisse

$15.01

-0.2 (-1.31%)

19:42
06/21/18
06/21
19:42
06/21/18
19:42
Periodicals
Federal judge rules in Credit Suisse favor in a $300M broker suit, Reuters says »

A San Francisco federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$26.45

-0.8 (-2.94%)

, FUJIY

Fujifilm

$0.00

(0.00%)

19:19
06/21/18
06/21
19:19
06/21/18
19:19
Periodicals
Xerox judge rejects Fuji request to end deal vote injunction, Bloomberg says »

Fujifilm Holdings (FUJIY)…

XRX

Xerox

$26.45

-0.8 (-2.94%)

FUJIY

Fujifilm

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

19:11
06/21/18
06/21
19:11
06/21/18
19:11
Hot Stocks
Airbus says no-deal Brexit would lead to 'severe disruption' of U.K. production »

Airbus said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

, MDT

Medtronic

$86.29

0.11 (0.13%)

19:00
06/21/18
06/21
19:00
06/21/18
19:00
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Tandem Diabetes…

TNDM

TNDM

MDT

Medtronic

$86.29

0.11 (0.13%)

RHT

Red Hat

$165.62

-3.64 (-2.15%)

VMW

VMware

$152.08

-0.07 (-0.05%)

SPLK

Splunk

$113.06

-2.8 (-2.42%)

SGH

Smart Global

$39.79

-0.72 (-1.78%)

TCS

Container Store

$8.73

0.08 (0.92%)

LRCX

Lam Research

$176.01

1.54 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

  • 21

    Jun

  • 22

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 07

    Jul

  • 09

    Jul

  • 10

    Jul

  • 10

    Jul

  • 10

    Jul

  • 12

    Jul

  • 12

    Jul

  • 12

    Jul

BDRBF

Bombardier

$0.00

(0.00%)

, ERJ

Embraer

$25.48

-0.2 (-0.78%)

18:53
06/21/18
06/21
18:53
06/21/18
18:53
Periodicals
Bombardier sees CRJ 900 winning 'half or more' of market share, Reuters says »

Bombardier's (BDRBF)…

BDRBF

Bombardier

$0.00

(0.00%)

ERJ

Embraer

$25.48

-0.2 (-0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

  • 02

    Aug

WOW

WideOpenWest

$9.44

-0.2497 (-2.58%)

18:37
06/21/18
06/21
18:37
06/21/18
18:37
Initiation
WideOpenWest initiated at B. Riley FBR »

WideOpenWest initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CABO

Cable One

$716.20

-2.81 (-0.39%)

18:37
06/21/18
06/21
18:37
06/21/18
18:37
Initiation
Cable One initiated at B. Riley FBR »

Cable One initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

, DIS

Disney

$105.89

-1.39 (-1.30%)

18:32
06/21/18
06/21
18:32
06/21/18
18:32
Hot Stocks
Disney offers to divest Fox assets generating up to $1B in EBITDA »

In a regulatory filing,…

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

DIS

Disney

$105.89

-1.39 (-1.30%)

CMCSA

Comcast

$32.80

-0.595 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$86.29

0.11 (0.13%)

18:29
06/21/18
06/21
18:29
06/21/18
18:29
Hot Stocks
Medtronic announces FDA approval of MiniMed 670G system »

Medtronic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

AEO

American Eagle

$25.27

0.615 (2.49%)

18:23
06/21/18
06/21
18:23
06/21/18
18:23
Hot Stocks
American Eagle director Page sells 44,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,157.63

-11.75 (-1.00%)

, GOOGL

Alphabet Class A

$1,169.56

-14.27 (-1.21%)

18:19
06/21/18
06/21
18:19
06/21/18
18:19
Periodicals
YouTube to let content creators sell monthly subscriptions, Bloomberg says »

Google's YouTube is…

GOOG

Alphabet

$1,157.63

-11.75 (-1.00%)

GOOGL

Alphabet Class A

$1,169.56

-14.27 (-1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

NMR

Nomura

$4.85

-0.075 (-1.52%)

18:09
06/21/18
06/21
18:09
06/21/18
18:09
Periodicals
Nomura to cut 40 global markets traders in the U.S., Bloomberg says »

Nomura is expected to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$120.06

-0.2 (-0.17%)

18:02
06/21/18
06/21
18:02
06/21/18
18:02
Hot Stocks
SPDR Gold Trust holdings fall to 824.63MT from 828.76MT »

This is the first decline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.37

-0.13 (-0.24%)

17:50
06/21/18
06/21
17:50
06/21/18
17:50
Periodicals
Wells Fargo said to let go of 10 analysts to cut costs, Bloomberg reports »

Wells Fargo has laid off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

  • 12

    Apr

  • 16

    Jul

  • 15

    Oct

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

, DIS

Disney

$105.89

-1.39 (-1.30%)

17:47
06/21/18
06/21
17:47
06/21/18
17:47
Periodicals
Breaking Periodicals news story on 21st Century Fox, Disney, Comcast »

Disney to double asset…

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

DIS

Disney

$105.89

-1.39 (-1.30%)

CMCSA

Comcast

$32.80

-0.595 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.